Article

Bid signal pathway components are identified in the temporal cortex with Parkinson disease

Mayo Clinic Scottsdale (C.H.A.), Scottsdale, AZ
Neurology (Impact Factor: 8.29). 09/2012; 79(17):1767-73. DOI: 10.1212/WNL.0b013e3182703f76
Source: PubMed

ABSTRACT

Parkinson disease (PD), a devastating neurodegenerative disorder, affects motor abilities and cognition as well. It is not clear whether the proapoptotic protein, Bid, is involved in tumor necrosis factor death receptor I (TNFRI)-mediated destructive signal transduction pathways such as cell dysfunction or neurodegeneration in the temporal cortex of patients with PD.
Molecular and biochemical approaches were used to dissect mitochondrial related components of the destructive signaling pathway in the temporal cortex from rapidly autopsied brains (postmortem interval mean 2.6 hours). Brains from patients with PD (n = 15) had an average age of 81.4 years, compared to the average age of 84.36 years in age-matched control patient brains (n = 15).
TNFRI and its adaptor protein, TRADD, were not only present in the cytoplasm of the temporal cortex, but were significantly elevated (42.3% and 136.1%, respectively) in PD brains compared to age-matched control brains. Bid in the PD temporal cortex could be further cleaved into tBid in the cytosol, which is translocated into the mitochondria, where cytochrome c is then released and caspase-3 is subsequently activated.
Patients with PD have an activated Bid-mediated destructive signal pathway via TNFRI in the temporal cortex. Such deficits are pervasive, suggesting that they might contribute to cortex degeneration as PD manifests.

Download full-text

Full-text

Available from: Rena Li, Feb 03, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: In Parkinson disease (PD), dopaminergic neuronal death within the substantia nigra generates characteristic motor manifestations, while synuclein pathology in cortical regions often causes additional symptoms, including cognitive impairment and dementia.(1) Therefore, a comprehensive understanding of PD pathogenesis requires the evaluation of cell death mechanisms both within the brainstem and extranigral sites. In the current issue of Neurology®, Jiang et al.(2) begin to reveal the potential molecular pathways responsible for cortical degeneration in PD.
    No preview · Article · Sep 2012 · Neurology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ginsenoside Rg1 (Rg1) is a major bioactive ingredient in Panax ginseng that has low toxicity and has been shown to have neuroprotective effects. The objectives of the present study were to explore the potential of the application of Rg1 for the treatment of Parkinson's disease (PD) and to determine whether its neuroprotective effects are exerted through the Wnt/β-catenin signaling pathway by using in vivo and in vitro models of PD. In the in vivo study, Rg1 treatment ameliorated the behavioral deficits of "Pole test", and reduced dopaminergic cell loss that were induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP) in a dose-dependent manner in an in vivo model of PD. In the in vitro study, cell viability was increased and cell apoptosis induced by 1-methyl-4-phenylpyridinium(MPP+) was decreased by Rg1 pretreatment. Rg1 induced protective effects on the protein and mRNA expression levels of markers of the Wnt/β-catenin signaling pathway in both the in vivo and the in vitro studies, and these neuroprotective effects were blocked by DKK1 in the in vitro study. Our results provide evidence that Rg1 has neuroprotective effects in both in vivo and in vitro PD models, and these effects act through the Wnt/β-catenin signaling pathway. Taken together, these results indicate that Rg1 may exert therapeutic effects on PD via the Wnt/β-catenin signaling pathway and may therefore provide a novel approach for the treatment of PD.
    No preview · Article · Oct 2015 · Neuropharmacology